Treat your cervical lesions by reducing HPV and precancerous risk factors with DeflaGyn® vaginal gel

GET ACTIVE

Pap test and Human Papillomavirus (HPV)

Icon 1

PAP test result can be normal, unclear or abnormal. If the results are unclear, further observation or other measures may be required to determine the risk.

Pap Test Results

Icon 1

Waiting periods are common when results are unclear. This allows the body to heal itself, while ensuring careful monitoring of any possible changes.

Watchful Waiting

Icon 1

Waiting periods are common when results are unclear. This allows the body to heal itself, while ensuring careful monitoring of any possible changes.

Keep in mind

  • Many unclear or abnormal findings may improve on their own – also described as remission and spontaneous regression – which justifies the watchful waiting strategy recommended in many national guidelines.
  • Publications consistently show that not only remission rates but also progression rates increase over time. The rate of progression to higher-grade lesions is reported as 16% during a 48-month period.
  • Even when initial cytological findings are still non-pathological, women who tested positive for HPV are at higher risk of developing precancerous lesions.
  • For all women, there is a risk that HPV infection becomes chronic and precancerous lesions progress to invasive cervical cancer.
  • The earlier HPV-induced changes are detected and treated, the better.
  • HPV infections that transform oncogenically can progress to cancer if untreated.
  • Women who test negative for oncogenic HPV have a much lower risk of cervical disease.

Why wait?

DeflaGyn® vaginal gel is specifically developed to provide treatment and support during this stressful "watchful waiting" period, in accordance with guidelines.

Most women do not want to wait! They get active during this time to help improve their condition.

Calm woman

DeflaGyn® vaginal gel - Certified Use

DEFLaGYN® VAGINAL GEL helps in spontaneous remission and regression of:

Improved Cytological Results

Icon 1

0%

BD SurePath™

is effective in enhancing remission and regression of cervical lesions and preventing their progression.
BD SurePath™

High-Risk HPV Clearance

Icon 1

0%

cobas 4800™

is a potential therapeutic regimen for patients with HPV-infected cervical lesions.
cobas 4800™

Reduced Oncogenic Risk

Icon 1

0%

CINtec

is effective in enhancing remission and regression of cervical lesions and preventing their progression.
CINtec

DeflaGyn® vaginal gel – Most Innovative Product of 2021 and 2022

DeflaGyn Gel

Pharma Trend is the reference study for innovation and sustainability in pharmaceutical companies. The effectiveness and tolerability of products, as well as the benefits observed during treatment, are the most decisive criteria for awarding the "Most Innovative Product" award.

What distinguishes the "Most Innovative Product" award from other evaluations in the pharmaceutical industry is the jury itself.

Product benefits are evaluated exclusively by doctors, pharmacists and patients, based on their experience during treatment use.

Excellent efficacy and safety

Alek Škrivanek
Dr. Alek Škrivanek, MD, PhD – Croatia
Gynecologist
Osijek
"My experience spanning over three decades in the field of gynecology suggests that efficacy and safety are essential, especially for patients with recurrent concerns. DeflaGyn® is a clinically useful and highly tolerated option."
Gynecologist

Sensitive remission tendency during stressful "watchful waiting"

Johannes Huber
Univ. Prof. DDr. Johannes Huber – Austria
Univ. Hospital
Vienna
This new treatment option is associated with a high success rate in patients during the time interval until the next follow-up. For the first time, gynecologists have the opportunity to treat their patients during therapy-free periods until the next check-up in accordance with Guidelines. Thus, the stressful period of "watchful waiting" can be overcome and the remission tendency can be significantly supported with this treatment.
Univ. Hospital

Exceptionally favorable risk-benefit profile

Doris Maria Gruber
Univ. Prof. Dr. Doris Maria Gruber – Austria
Univ. Hospital
Vienna
Gynecologists know the fact of increasing spontaneous remission rates with longer observation periods, but also take into account the increase in progression rates within the same periods. Furthermore, the remission tendency decreases with increasing age of the women in question, while at the same time the tendency for neoplasia increases. Considering the good tolerability and toxicological safety of the gel, the risk-benefit profile of DeflaGyn® vaginal gel application is exceptionally favorable.
Univ. Hospital

Revolution in the treatment of precancerous stages

Attila Major
Prof. DDDr. Attila Major – Switzerland
Femina Gyn. Center
Geneva
From current literature and current gynecological experience, it is evident that a reduction in the number of bacteria, neutralization of existing viruses as well as a barrier and protection of epithelial cells from oxidants are desirable. From my experience, it can be concluded that DeflaGyn® vaginal gel will not only enrich the treatment of precancerous stages in adolescents and young women, in pregnant women and in particularly complicated situations, but will also revolutionize it.Femina Gyn. Center
Geneva